Abstract:Monoclonal antibodies (mAbs) targeting the SARS-CoV-2 receptor-binding domain (RBD) showed high efficacy in the prevention and treatment of COVID-19. However, the rapid evolution of SARS-CoV-2 has rendered all clinically authorized mAbs ineffective and continues to stymie the development of next-generation mAbs. Consequently, the ability to identify broadly neutralizing antibodies (bnAbs) that neutralize both current and future variants is critical for successful antibody therapeutic development, especially for newly emerged viruses when no knowledge about immune evasive variants is available. Here, we have developed a strategy to specifically select for potent bnAbs with activity against both existing and prospective SARS-CoV-2 variants based on accurate viral evolution prediction informed by deep mutational scanning (DMS). By adopting this methodology, we increased the probability of identifying XBB.1.5-effective SARS-CoV-2 bnAbs from ∼1% to 40% if we were at the early stage of the pandemic, as revealed by a retrospective analysis of >1,000 SARS-CoV-2 wildtype (WT)-elicited mAbs. From this collection, we identified a bnAb, designated BD55-1205, that exhibited exceptional activity against historical, contemporary, and predicted future variants. Structural analyses revealed extensive polar interactions between BD55-1205 and XBB.1.5 receptor-binding motif (RBM), especially with backbone atoms, explaining its unusually broad reactivity. Importantly, mRNA-based delivery of BD55-1205 IgG to human FcRn-expressing transgenic mice resulted in high serum neutralizing titers against selected XBB and BA.2.86 subvariants. Together, the ability to identify bnAbs via accurate viral evolution prediction, coupled with the speed and flexibility of mRNA delivery technology, provides a generalized framework for the rapid development of next-generation antibody-based countermeasures against SARS-CoV-2 and potentially other highly variable pathogens with pandemic potential.

The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2

Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients

Diverse Immunoglobulin Gene Usage and Convergent Epitope Targeting in Neutralizing Antibody Responses to SARS-CoV-2

Potent and Protective IGHV3-53/3-66 Public Antibodies and Their Shared Escape Mutant on the Spike of SARS-CoV-2.

A key F27I substitution within HCDR1 facilitates the rapid maturation of P2C-1F11-like neutralizing antibodies in a SARS-CoV-2-infected donor

Shared IGHV1-69-encoded Neutralizing Antibodies Contribute to the Emergence of L452R Substitution in SARS-CoV-2 Variants

Identification of Human Single-Domain Antibodies Against SARS-CoV-2.

Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2

Fortuitous somatic mutations during antibody evolution endow broad neutralization against SARS-CoV-2 Omicron variants

Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents

Structural basis of a shared antibody response to SARS-CoV-2

Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection

High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2

A generalized framework to identify SARS-CoV-2 broadly neutralizing antibodies

Single Cell and Immune Repertoire Profiling of COVID-19 Patients Reveal Novel Therapeutic Candidates

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies As Promising Therapeutics Against SARS-CoV-2 Infection

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants